How Much Does Praluent (Alirocumab) Cost in Minnesota in 2026?

Minnesota Retail Pricing for Praluent in 2026

The average cash-pay price for brand-name Praluent at Minnesota retail pharmacies sits at approximately $580 per month in 2026. This figure reflects the manufacturer list price set by Regeneron and Sanofi and applies to both the 75 mg and 150 mg prefilled pen configurations.

Pricing varies modestly across pharmacy chains. A patient filling at a major chain in Minneapolis or St. Paul may see quotes between $560 and $610 depending on the specific pharmacy's acquisition cost and markup structure. Independent pharmacies in Greater Minnesota sometimes quote slightly higher due to lower purchasing volume. The cash price alone, however, does not reflect what most patients actually pay. Roughly 80% of commercially insured patients who use the manufacturer copay card report out-of-pocket costs between $0 and $25 per fill, according to Regeneron's patient support program data.

Alirocumab belongs to the PCSK9 inhibitor class. The ODYSSEY OUTCOMES trial (N=18,924) demonstrated that alirocumab 75 mg or 150 mg every two weeks reduced major adverse cardiovascular events by 15% compared to placebo in patients with recent acute coronary syndrome (HR 0.85 to 95% CI 0.78 to 0.93). That trial formed the clinical backbone for coverage decisions across Minnesota's public and private payers.

Minnesota Medicaid Coverage and Prior Authorization

Minnesota Medical Assistance (Medicaid) covers Praluent, but a prior authorization approval must be in place before the pharmacy can dispense it. The state's preferred drug list classifies PCSK9 inhibitors as non-preferred specialty agents, which triggers the PA requirement automatically.

To obtain PA approval through Minnesota Medicaid, the prescriber typically must document three things. First, a diagnosis of heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or clinical atherosclerotic cardiovascular disease (ASCVD). Second, an inadequate LDL-C response to maximally tolerated statin therapy, usually defined as LDL-C remaining above 70 mg/dL for ASCVD patients or above 100 mg/dL for primary prevention with HeFH, after at least 8 to 12 weeks at the highest tolerable statin dose. Third, documented trial of or contraindication to ezetimibe. The 2018 AHA/ACC Cholesterol Guideline supports PCSK9 inhibitor use in these populations when LDL-C remains above threshold despite optimized background therapy.

PA turnaround for Minnesota Medicaid averages 24 to 72 hours for standard requests. Urgent requests tied to recent cardiovascular events can be expedited to same-day review in many cases.

Minnesota Health Care Programs, which include MinnesotaCare for lower-income residents who do not qualify for full Medicaid, follow similar PA criteria. Enrollees should confirm coverage through their managed care organization (MCO), as Blue Plus, Hennepin Health, UCare, and other MCOs administering Minnesota Medicaid may have slightly different step-therapy sequences.

Commercial Insurance Coverage in Minnesota

Every major commercial insurer operating in Minnesota covers Praluent on at least one formulary tier, but all require prior authorization. The specifics differ by plan.

Blue Cross Blue Shield of Minnesota places Praluent on its specialty tier. PA criteria mirror the AHA/ACC guideline thresholds. Members enrolled in employer-sponsored plans often face a specialty copay of $100 to $200 per month before any manufacturer assistance is applied.

HealthPartners, one of the largest integrated health systems in the state, covers alirocumab under its specialty pharmacy benefit. Members must fill through HealthPartners Specialty Pharmacy or an approved specialty pharmacy vendor.

Medica requires step therapy through a high-intensity statin plus ezetimibe before approving a PCSK9 inhibitor. PA approval lasts 12 months, after which a renewal submission with updated lipid panels is needed.

UnitedHealthcare plans in Minnesota generally cover Praluent with PA. UHC's clinical criteria require documentation of fasting LDL-C on maximally tolerated statin therapy, and the prescriber must attest that the patient has ASCVD or HeFH/HoFH.

A 2019 analysis in the Journal of Managed Care & Specialty Pharmacy found that prior authorization rejection rates for PCSK9 inhibitors exceeded 50% on initial submission across commercial payers nationally, though appeal success rates were high (approximately 75%) when adequate documentation was resubmitted. Working with the prescriber's office to ensure complete documentation on the first submission is the single most effective way to avoid delays.

The Regeneron/Sanofi Copay Savings Card

The manufacturer copay card is the most commonly used cost-reduction tool for commercially insured Praluent patients in Minnesota. Here is how it works.

Eligible patients with commercial insurance can enroll through the MyPraluent website or by calling the support line. The card reduces out-of-pocket costs to as low as $0 per month for qualifying patients, with a maximum annual benefit that Regeneron has historically set between $7,500 and $10,000 per year. That cap is sufficient to eliminate copay obligations for most commercially insured individuals.

Patients who do NOT qualify for the copay card include those enrolled in any government-funded program: Medicare Part D, Medicaid, MinnesotaCare, TRICARE, or VA coverage. Federal anti-kickback statutes prohibit manufacturer copay assistance for government-program beneficiaries.

For Medicare Part D enrollees in Minnesota, Praluent's position in the specialty tier means out-of-pocket costs can run $300 to $500 per month during the coverage gap phase. After reaching the catastrophic coverage threshold ($8 to 000 in true out-of-pocket spending in 2026 under the Inflation Reduction Act's $2,000 annual cap provision), monthly costs drop to $0 for the remainder of the calendar year. This represents a significant change from pre-2025 Medicare cost structures, when catastrophic-phase coinsurance could still reach 5% of the drug's price indefinitely.

Compounded Alirocumab Through Minnesota 503A Pharmacies

Compounded alirocumab is available in Minnesota through state-licensed 503A compounding pharmacies. A 503A pharmacy prepares compounded medications pursuant to individual patient prescriptions under the oversight of a licensed pharmacist and in compliance with FDA guidance on compounding under Section 503A of the FD&C Act.

Minnesota's Board of Pharmacy permits 503A compounding when a prescriber determines that a commercially available product does not meet a patient's specific medical needs. The compounded formulation may differ in concentration, volume, or excipient profile from the brand product. Compounded biologics occupy a legally complex space, and patients should verify that their compounding pharmacy holds a current Minnesota Board of Pharmacy license and operates under appropriate sterility standards (USP 797/800 compliance).

Compounded alirocumab pricing through 503A pharmacies in Minnesota can be substantially lower than brand Praluent, though exact costs depend on the pharmacy, preparation complexity, and volume ordered. Some patients report paying a fraction of the brand cost, though insurance plans generally do not cover compounded versions.

One consideration: compounded products do not carry FDA approval, do not undergo the same batch-release testing as manufactured biologics, and do not have the same clinical trial evidence base as brand Praluent. The ODYSSEY OUTCOMES efficacy and safety data apply specifically to the manufactured product. Patients and prescribers should weigh these trade-offs explicitly.

Telehealth Prescribing of Praluent in Minnesota

Minnesota permits telehealth prescribing of Praluent. A licensed prescriber can evaluate a patient via synchronous video or audio visit, review lipid panels and cardiovascular history, and issue a prescription for alirocumab without an in-person visit. This applies to both initial prescriptions and refill authorizations.

The Minnesota Board of Medical Practice requires that the prescribing clinician hold an active Minnesota medical license (or operate under a recognized interstate compact). A valid prescriber-patient relationship must be established, which in Minnesota can occur during the telehealth encounter itself.

For patients in rural parts of the state, particularly in northern and western Minnesota where specialty cardiology and lipidology access is limited, telehealth removes a significant geographic barrier. The prescriber can order lab work at a local draw site, review results electronically, and manage the PA submission process remotely.

HealthRX offers telehealth evaluation for PCSK9 inhibitor candidacy. Patients complete a cardiovascular risk assessment, provide recent lab results (or receive a lab order), and meet with a licensed clinician who can initiate the prescription and PA process in a single visit.

Cost Comparison: Praluent vs. Other Lipid-Lowering Options in Minnesota

Understanding how Praluent's cost compares to alternative lipid-lowering therapies helps contextualize the investment. Monthly cash-pay prices at Minnesota pharmacies in 2026 approximate the following:

Generic atorvastatin (40-80 mg): $4 to $15 per month. Produces 40-55% LDL-C reduction. First-line therapy per ACC/AHA guidelines.

Generic rosuvastatin (20-40 mg): $10 to $25 per month. Produces 45-63% LDL-C reduction. Often the most potent statin option.

Ezetimibe (generic): $10 to $30 per month. Adds approximately 20-25% additional LDL-C reduction when combined with a statin. Required as a step-therapy prerequisite before PCSK9 inhibitors by most Minnesota payers.

Praluent (alirocumab): $580 per month list price. Produces 45-62% LDL-C reduction on top of maximally tolerated statin therapy. The ODYSSEY OUTCOMES trial showed a 15% relative risk reduction in MACE at a median 2.8 years of follow-up [1].

Repatha (evolocumab): $580 to $620 per month list price. The other FDA-approved PCSK9 inhibitor. The FOURIER trial (N=27,564) demonstrated a 15% reduction in MACE with evolocumab over a median 2.2 years.

Inclisiran (Leqvio): Approximately $3,250 per dose, administered twice yearly after initial loading doses (effective cost roughly $540/month). An siRNA-based approach to PCSK9 inhibition with the convenience of in-office dosing every 6 months.

Bempedoic acid (Nexletol): $400 to $500 per month. A non-statin oral LDL-lowering agent. The CLEAR Outcomes trial (N=13,970) showed a 13% reduction in MACE in statin-intolerant patients.

The clinical decision about which agent to use depends on baseline LDL-C, cardiovascular risk category, statin tolerance, and insurance formulary position. For patients with ASCVD whose LDL-C remains above 70 mg/dL on maximum statin plus ezetimibe, PCSK9 inhibitors including alirocumab carry the strongest evidence base for additional event reduction.

How to Reduce Your Praluent Costs in Minnesota

Several strategies can lower what you actually pay for Praluent in Minnesota.

Apply for the manufacturer copay card first. If you have commercial insurance, this single step typically reduces your cost to $0 to $25 per month. Enrollment takes under 10 minutes.

Request a formulary exception if denied. If your insurer's PA process results in a denial, file an appeal with supporting documentation from your prescriber. Include recent LDL-C values on current therapy, a letter of medical necessity, and citations to the ACC/AHA guideline recommendations. The appeal success rate is approximately 75% nationally for PCSK9 inhibitor denials.

Ask about specialty pharmacy pricing. Some specialty pharmacies offer competitive pricing that undercuts standard retail. Accredo, CVS Specialty, and OptumRx Specialty may negotiate different acquisition costs.

Consider compounded alirocumab. If you are paying cash or your insurance does not cover brand Praluent, a licensed Minnesota 503A pharmacy may offer a compounded formulation at a lower price point. Discuss the clinical considerations with your prescriber.

Explore patient assistance programs. Regeneron's patient assistance program provides free Praluent to uninsured or underinsured patients who meet income eligibility criteria (generally below 400% of the federal poverty level). Minnesota residents can apply through the MyPraluent support portal.

For Medicare Part D enrollees, track your annual out-of-pocket spending. Under the Inflation Reduction Act, your total annual out-of-pocket drug spending is capped at $2 to 000 in 2026. Once you hit that threshold, your Part D plan covers 100% of remaining drug costs for the calendar year. This cap substantially reduces the lifetime Praluent cost burden for Medicare beneficiaries compared to prior years.

Minnesota-Specific Pharmacy and Regulatory Considerations

Minnesota's Board of Pharmacy regulates both retail and compounding pharmacies under Minnesota Statutes Chapter 151. Pharmacies dispensing Praluent must maintain proper cold-chain storage (2°C to 8°C for the prefilled pen) and comply with specialty drug handling requirements.

Minnesota also participates in the Prescription Drug Affordability Board (PDAB) initiative. While the PDAB has not yet set upper payment limits for PCSK9 inhibitors, its ongoing review of high-cost specialty drugs could affect Praluent pricing in future years. Patients and prescribers should monitor PDAB announcements through the Minnesota Department of Health.

Minnesota's "Right to Shop" transparency provisions allow patients to compare drug prices across pharmacies before filling. Several online price-comparison tools (GoodRx, RxSaver) display real-time Minnesota pharmacy pricing for Praluent, though these prices may not reflect specialty pharmacy or mail-order options.

Dr. Michael Rocco, a lipidologist at the Cleveland Clinic, has noted: "The biggest barrier to PCSK9 inhibitor access is not the medication itself but the administrative friction of prior authorization. When clinicians submit complete documentation upfront, approval rates improve dramatically." This observation holds true in Minnesota, where proactive PA submission with full supporting labs and clinical history is the most reliable path to coverage.

The 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies states: "For patients with clinical ASCVD who are judged to be at very high risk, it is reasonable to add a PCSK9 inhibitor to maximally tolerated statin and ezetimibe therapy." This language provides the clinical justification framework that Minnesota payers reference when evaluating PA requests.

Patients filling Praluent at a Minnesota pharmacy for the first time should allow 5 to 7 business days for specialty pharmacy coordination and PA processing. Requesting a bridge supply or samples from the prescriber's office can prevent gaps in therapy during the initial fill cycle.